Reactivation of latent tuberculosis by an inhibitor of inducible nitric oxide synthase in an aerosol murine model

Immunology

Volumn 107, Issue 3, 2002, Pages 350-357

  Botha, Tania ^a   Ryffel, Bernhard ^b  

^a CAPE PENINSULA UNIVERSITY OF TECHNOLOGY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; ISONIAZID; RIFAMPICIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; GRANULOMA; IMMUNE SYSTEM; IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; MALE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GUANIDINES; IMMUNOSUPPRESSION; LUNG; MALE; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RECURRENCE; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036433061     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2002.01511.x     Document Type: Article

References (17)

1. Sudre P, Ten Dam G, Kochi A. Tuberculosis: A global overview of the situation today. Bull WHO 1992; 70:149-59.
2. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 1991; 72:1-6.
3. Stead WW. Pathogenesis of a first episode of chronic pulmonary tuberculosis in man: Recrudescence of residuals of the primary infection or exogenous reinfection? Am Rev Resp Dis 1967; 95:729-45.
4. Raviglione MC, Snider DE, Kochi A. Global epidemiology of tuberculosis: Morbidity and mortality of a global epidemic. JAMA 1995; 273:220-6.
5. Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons: A prospective cohort study. JAMA 1995; 274:143-8.
6. Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries: Epidemiology and strategies for prevention. Tuber Lung Dis 1992; 73:311-21.
7. McCune RM, Feldmann FM, McDermott W. Microbial persistence II. Characteristics of the sterile state of tubercle bacilli. J Exp Med 1966; 123:469-86.
8. McCune RM, Feldmann FM, Lambert HP, McDermott W. Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. J Exp Med 1966; 123:445-68.
9. Brown DH, Miles BA, Zwilling BS. Growth of Mycobacterium tuberculosis in BCG-resistant and -susceptible mice: Establishment of latency and reactivation. Infect Immunol 1995; 63:2243-7.
10. Orme IM. A mouse model of the recrudescence of latent tuberculosis in the elderly. Am Rev Respir Dis 1988; 137:716-8.
11. Flynn JL, Scanga CA, Tanaka KE, Chan J. Effects of aminoguanidine on latent murine tuberculosis. J Immunol 1998; 160:1796-803.
12. Mustafa T, Phyu S, Nilsen R, Johnson Bjune G. A mouse model for slowly progressive primary tuberculosis. Scand J Immunol 1999; 50:127-36.
13. Phyu S, Mustafa T, Hofstad T, Nilsen R, Fosse R, Bjune G. A mouse model for latent tuberculosis. Scand J Infect Dis 1998; 30:59-68.
14. Scanga CA, Mohan VP, Joseph H, Yu K, Chan J, Flynn JL. Reactivation of latent tuberculosis: Variations on the Cornell murine model. Infect Immun 1999; 67:4531-8.
15. Marino MW, Dunn A, Grail D et al. Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci USA 1997; 94:8093-8.
16. Barry C, Cole S, Fourie B et al. Scientific blueprint for TB drug development. Tuberculosis 2001; 81 (Suppl. 1):1-52.
17. Grosset J. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull Int Union Tuberc 1978; 53 [1(Intanbul number)]:5-12.